Abstract: The invention relates to a process for the recovery and recycling of the iodine from aqueous solutions comprising iodine-comprising aromatic compounds in which the iodine contained in said aromatic compounds is directly converted into molecular iodine at a pH lower than 1, in the absence of a catalyst.

Abstract: The present specification provides methods of treating disease with an ester of an RXR agonist or a combination of an ester of an RXR agonist and a thyroid hormone. The esters of an RXR agonist can be useful in the treatment of cancer, nervous system, autoimmune, and muscular disorders.

Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Abstract: Continuous process for co-production of acetic acid and acetic anhydride by contacting carbon monoxide with a liquid reaction composition containing methyl acetate, dimethyl ether or a mixture thereof, a Group VIII metal catalyst, methyl iodide, acetic acid, acetic anhydride, and water in a concentration of 0.1 wt % or less, withdrawing liquid reaction composition from the reaction zone, introducing at least a portion thereof into a flash separation zone, and removing from the flash separation zone a vapor fraction containing acetic anhydride, acetic acid and methyl iodide and a liquid fraction containing acetic anhydride, and Group VIII metal catalyst. The liquid reaction composition and the withdrawn liquid reaction composition introduced into the flash separation zone contains a Group IA and/or Group IIA metal salt and the molar ratio of acetic acid to acetic anhydride in the vapor fraction removed from the flash separation zone is greater than or equal to 1.

Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Abstract: Provided herein are compounds useful for the preparation of compounds that have retinoid-like biological activity. Also provided herein are processes for the preparation of compounds that have retinoid-like biological activity.

Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Abstract: The present specification provides RXR agonist compounds, compositions comprising such RXR agonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such RXR agonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.

Abstract: The present invention relates to a process for synthesizing a multifunctional compound, including the reaction of a compound of formula (II) with atmospheric or molecular oxygen, in the presence of at least one aldehyde of formula (III), and optionally in the presence of at least one catalyst or at least one radical initiator; wherein: R10, R20, R30, R40, R50, L2, R60, R7, R8, and R9 are as described in the claims. The invention also relates to the use of these compounds as monomers for the preparation of polyurethane. The invention also relates to the use of these compounds as monomers of polymers or of biopolymers.

Abstract: A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C?O)R9, —(C?O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; R3 is hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R4 is hydrogen, alkyl, aryl, alkenyl, cycloalkyl, or heterocyclic all either substituted or unsubstituted; R5, R6, R7, and R8 are independently hydrogen, halogen, cyano, alkoxy, NHCOR9, NHSO2R9, COOR9, OCOR9, aryl, alkyl, alkenyl, cycloalkyl, alkoxyaryl or heterocyclic all either substituted or unsubstituted, or combine with each other, or R5 can combine with R4 to form a carbocyclic or heterocyclic ring; R9 and R10 are independently alkyl, alkoxy, aryl, naphthyl, styryl, alkenyl, cycloalkyl, alko

Abstract: A binaphthyl compound represented by General Formula (G1) is provided. In General Formula (G1), Ar2 represents any of an arylene group, a cycloalkylene group, and a cycloalkenylene group, and m is any of 0 to 3; R3 represents any of hydrogen, an alkyl group, and an alkoxy group; and one of R and R1 represents a substituent represented by General Formula (G2) and the other thereof represents hydrogen. In General Formula (G2), Ar1 represents any of an arylene group, a cycloalkylene group, and a cycloalkenylene group, and k is any of 1 to 3; and R2 represents any of hydrogen, an alkyl group, and an alkoxy group.

Abstract: The present invention is to provide a novel polymerizable chiral compound (chiral agent) having high left-handed helical twisting power, a polymerizable liquid crystal composition comprising the polymerizable chiral compound and a polymerizable liquid crystal compound, a liquid crystal polymer, and an optically anisotropic body.

Abstract: A sulfonium salt having a 4-fluorophenyl group is introduced as recurring units into a polymer comprising hydroxyphenyl(meth)acrylate units and acid labile group-containing (meth)acrylate units to form a polymer which is useful as a base resin in a resist composition. The resist composition has a high sensitivity, high resolution and minimized LER.

Abstract: The invention relates to a process for preparing aryl- and heteroarylacetic acids and derivatives thereof by reaction of aryl or heteroaryl halides with malonic diesters in the presence of a palladium catalyst, of one or more bases and optionally of a phase transfer catalyst. This process enables the preparation of a multitude of functionalized aryl- and heteroarylacetic acids and derivatives thereof, especially also the preparation of arylacetic acids with sterically demanding substituents.

Abstract: The present invention relates to an acrylate-based compound that includes an organic acid having two or more acrylate groups and one or more phenolic acid structures in one molecule, and a photosensitive composition including the same. It is possible to shorten a developing time in a photolithography process without damaging photosensitivity by using the photosensitive composition according to the present invention.

Abstract: A liquid crystal composition comprising a chiral dopant compound represented by the following structure (Structure 1): wherein: R1 and R2 are independently hydrogen, —(C?O)R9, —(C?O)R10, alkyl, aryl, alkaryl, alkenyl, cycloalkyl, alkoxyaryl, or heterocyclic all either substituted or unsubstituted, or combine to form a carbocyclic or heterocyclic ring; and R3-R9 are as described in the disclosure. Also featured are liquid crystal compositions comprising a chiral dopant compound represented by any of Structure 2-4 as described in the disclosure.

Abstract: The invention relates to an immersion liquid including at least one compound of the general formula I in which R1 and R2 each include at least one ring structure and X denotes: O, S, NR3 with R3 selected from hydrogen or hydrocarbon, wherein Y denotes independently of each other O, S or NR4 with R4 selected from hydrogen or hydrocarbon. In addition, the invention relates to a further immersion liquid, a compound for an immersion liquid and a use of the immersion liquids or of the compound as an immersion oil for a microscope, in particular for a near-field microscope.

Abstract: The invention relates to the use of compounds having a monogalactosyldiacylglycerol (MGDG) synthase inhibitory activity as herbicide or algaecide, and to herbicide and algaecide compositions containing at least one of these compounds.

Abstract: The invention relates to compounds of general formula I, (I), wherein R is wherein R is aryl substituted by R3; or R is (C3-Ci3)-cycloalkyl, (C3-Ci3)-cycloalkenyl or (C7-Ci3)-cycloalkynyl optionally substituted by R4; and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use—alone or in combination with one or more other pharmaceutically active compounds—in therapy, for preventing, treating or ameliorating diseases or conditions responsive to stimulation of neutrophil oxidative burst, responsive to stimulation of keratinocyte IL-8 release or responsive to induction of necrosis.

Abstract: Methods for the synthesis and use of functionalized, substituted naphthalenes are described. The functionalized, substituted naphthalenes display useful properties including liquid crystals and fluorescence properties, such as solvatochromatic fluorescence, with high quantum yields, Stoke's shift, and show emission maxima that are significantly red-shifted.

Abstract: A production process for substituted phenylacetic acids or ester analogues thereof is disclosed. In this process toluene or toluene substituted with various substituents, an alcohol, an oxidant and carbon monoxide are used as raw materials to obtain compounds comprising structure of phenylacetic acid ester or analogues thereof by catalysis of the complex catalyst formed from transition metal and ligand, and such compounds are hydrolyzed to obtain various substituted phenylacetic acid based compounds. This type of compounds and their derivatives serve as important fine chemicals used widely in the industries of pharmaceuticals, pesticides, perfume and the like.

Abstract: A modified dimethylnaphthalene formaldehyde resin obtained by modifying a polyfunctional dimethylnaphthalene formaldehyde resin having a constituent unit represented by the following general formula [1] in a molecule thereof with at least one member selected from the group consisting of a phenol represented by the following general formula [2], a naphthol represented by the following general formula [3] and a naphthol represented by the following general formula [4] provided that at least any of the naphthol represented by the general formula [3] or the naphthol represented by the general formula [4] must be included.

Abstract: A modified dimethylnaphthalene formaldehyde resin obtained by modifying a polyfunctional dimethylnaphthalene formaldehyde resin having a constituent unit represented by the following general formula [1] in a molecule thereof with at least one member selected from the group consisting of a phenol represented by the following general formula [2], a naphthol represented by the following general formula [3] and a naphthol represented by the following general formula [4] provided that at least any of the naphthol represented by the general formula [3] or the naphthol represented by the general formula [4] must be included.

Abstract: The invention relates to compounds of the formula I in which R1, R2, X, A, B, Z and Y1 to Y4 have the meanings indicated in the claims, and/or a pharmaceutically acceptable salt and/or a prodrug thereof. Because of their properties as inhibitors of chemokine receptors, especially as CXCR2 inhibitors, the compounds of the formula I and the pharmaceutically acceptable salts and prodrugs thereof are suitable for the prevention and treatment of chemokine mediated diseases.

Abstract: Naproxen-based ferroelectric liquid crystal (FLC) or nematic liquid crystal chiral compounds, which can be used in liquid crystal compositions useful for electro-optical and display device applications. The liquid crystal can be a ferroelectric liquid crystal. Also provided is a display device that includes the Naproxen-based ferroelectric liquid crystal (FLC) or nematic liquid crystal chiral compound. Also provided is a method of preparing a liquid crystal display device on silicon that includes incorporating the Naproxen-based ferroelectric liquid crystal (FLC) or nematic liquid crystal chiral compound, into a liquid crystal display on silicon by disposing the compound in a liquid crystal, or the liquid crystal, onto a silicon surface.

Abstract: A molecular glass compound includes (A) a tetrameric reaction product of a specific aromatic compound having at least one hydroxy group, and a specific polycyclic or fused polycyclic aromatic aldehyde; and (B) an acid-removable protecting group as an adduct with the hydroxy group of the aromatic compound and/or a hydroxy group of the polycyclic or fused polycyclic aromatic aldehyde. A photoresist composition including the molecular glass compound, and a coated substrate including a layer of the photoresist composition are also disclosed.

Abstract: A molecular glass compound comprises a vinyl ether adduct of an aromatic vinyl ether of formula C(R1)2?C(R2)—O-(L)n-Ar1, and a calix[4]arene, wherein R1 and R2 are each independently a single bond, H, C1-20 alkyl, C1-20 haloalkyl, C6-20 aryl, C6-20 haloaryl, C7-20 aralkyl, or C7-20 haloaralkyl, L is a C1-20 linking group, n is 0 or 1, and Ar1 is a halo-containing monocyclic, or substituted or unsubstituted polycyclic or fused polycyclic C6-20 aromatic-containing moiety, wherein R1 and R2 are connected to Ar1 when either or both of R1 and R2 is a single bond and n is 0. A photoresist, comprising the molecular glass compound, a solvent, and a photoacid generator, a coated substrate, comprising (a) a substrate having one or more layers to be patterned on a surface thereof; and (b) a layer of a photoresist composition over the one or more layers to be patterned, and a method of forming the molecular glass compound, are also disclosed.

Abstract: The invention relates to compounds of Formula (I): The invention further relates to liquid crystal compositions comprising compounds of Formula (I); compositions further comprising one or more chiral compounds; and polymer networks derived from the polymerization of the liquid crystal compositions. Another embodiment relates to processes for providing compounds of Formula (I).

Abstract: Methods are described for efficient and regioselective reactions that are Ru-catalyzed and either (i) amide-directed C—H, C—N, C—O activation/C—C bond forming reactions, (ii) ester-directed C—O and C—N activation/C—C bond forming reactions, or (iii) amide-directed C—O activation/hydrodemethoxylation reactions. All of these reactions of directed C—H, C—N, C—O activation/coupling reactions establish a catalytic base-free DoM-cross coupling process at non-cryogenic temperature. High regioselectivity, yields, operational simplicity, low cost, and convenient scale-up make these reactions suitable for industrial applications. Many previously unknown amide-substituted or ester-substituted aryl and heteroaryl compounds are presented with synthetic details also provided.

Abstract: Disclosed are polyesters, particularly poly(trimethylene terephthalate), comprising fluorovinylether functionalized aromatic repeat units, and methods to make the polyester polymers. The polymers are useful for imparting soil resistance to polyesters, particularly in the form of fibers, fabrics, and carpets.

Abstract: It's object is to provide a (meth)acrylate compound excellent in photocurability, a curable composition comprising the compound and excellent in all of pattern accuracy, peelability, surface hardness, elasticity recovery and solvent resistance, an optical nanoimprint composition and a cured product of the curable composition and a method for producing it, especially to provide a composition favorable for a permanent film for flat panel displays, etc. A (meth)acrylate compound represented by the following formula (1): wherein R1 represents a hydrogen atom or a methyl group, R2 represents a substituent having carbon atoms of 2 to 6 and having a carbon-carbon double bond, X represents an organic group having carbon atoms of 1 to 10, m and n each are an integer of 1 to 3.

Abstract: The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.

Abstract: A compound of general formula I their use as calcium receptor-active compounds for the prophylaxis, treatment or amelioration of physiological disorders or diseases associated with disturbances of CaSR activity, such as hyperparathyroidism, pharmaceutical compositions comprising said compounds, methods of treating diseases with said compounds, and the use of said compounds in the manufacture of medicaments.

Abstract: The present invention relates to allosteric binding compounds of formula (I), especially for the treatment of CNS disorders, together with pharmaceutical compositions and methods of treatment including these compounds.

Abstract: Disclosed therein are a cyclic olefin compound, a photoreactive polymer, and an alignment layer comprising the photoreactive polymer, where the cyclic olefin compound can be used to provide the photoreactive polymer having not only excellences in liquid crystal alignment and alignment rate but also readiness for change in the alignment direction depending on the polarization direction.

Abstract: Disclosed is a method for producing an optically active ester by highly selectively esterifying one enantiomer of a racemic carboxylic acid, while producing an optically active carboxylic acid which is the other enantiomer. An optically active ester is produced while producing an optically active carboxylic acid at the same time by reacting a racemic carboxylic acid with a specific alcohol or phenol derivative in the presence of benzoic anhydride or a derivative thereof and a catalyst such as tetramisole or benzotetramisole, thereby selectively esterifying one enantiomer of the racemic carboxylic acid.

Abstract: A radioisotope labeled reagent includes a compound having the general formula (I), L-(aCbH2)naC5bH3??(I) where a in each occurrence independently is a carbon mass number between 11 and 14 inclusive, b in each occurrence independently is a hydrogen mass number between 1 and 3 inclusive, such that a in each occurrence is not 12 simultaneously with b in each occurrence being 1; L is a leaving group R1SO2—O—, R1—S—, 12C1H3(12C1H2)n—S—R1C(O)O—, NC—, (R1)3P—, XMg— and Li—, where n is an integer between 0 and 3 inclusive, where X is chloro, bromo or iodine, where R1 is H, aryl, a substituent containing aryl, C1-C20 alkyl, a substituent containing C1-C20 alkyl, C2-C20 alkenyl, a substituent containing C2-C20 alkenyl, C2-C20 alkynyl, and a substitute containing C2-C20 alkynyl with the proviso that when n is 0, a is 13 and b is 2 and R1 in R1—S is not aryl.

Abstract: This invention relates to liquid crystal compositions, and polymer networks and articles comprising the compositions. The compositions comprise at least one compound of the group of compounds represented by the structures of each of the following Formulas (IV), (V) and (VI), as defined herein. A process for making the composition is also provided.

Abstract: The present invention relates to a novel process for preparing ?-arylmethylcarbonyl compound of the formula (III), characterized in that aryl- and heteroarylacetic acids and derivatives thereof of the formula (I) are reacted with ?-halomethylcarbonyl compounds of the formula (II) in the presence of a palladium catalyst, of a phosphine ligand, of an inorganic base and of a phase transfer catalyst, optionally using an organic solvent.

Abstract: The invention relates to the use as perfuming ingredients of 8a-alkyl-perhydro-naphthalenol derivatives, to impart odor notes of the woody-earthy type.

Abstract: The present invention relates to novel, non-secosteroidal, phenyl-naphthalene compounds of Formula (I): wherein R, R1, RP, ZP, LP1, LP2 LNP, RP3, RN, and ZNP are defined herein, their preparation, pharmaceutical compositions, and methods of use.

Abstract: Embodiments of the invention provide methods and materials for chemical cross-coupling reactions that utilize unconventional phenol derivatives as cross-coupling partners. Embodiments of the invention can be used to synthesize a variety of useful organic compounds, for example the anti-inflammatory drug flurbiprofen.

Abstract: The invention relates to an immersion liquid including at least one compound of the general formula I in which R1 and R2 each include at least one ring structure and X denotes: O, S, NR3 with R3 selected from hydrogen or hydrocarbon, wherein Y denotes independently of each other O, S or NR4 with R4 selected from hydrogen or hydrocarbon. In addition, the invention relates to a further immersion liquid, a compound for an immersion liquid and a use of the immersion liquids or of the compound as an immersion oil for a microscope, in particular for a near-field microscope.

Abstract: A polymerizable liquid crystal compound of formula (1). The compound has high optical (refractive index) anisotropy (?n), exhibits a liquid crystal phase at room temperature (having a broad liquid crystal phase temperature range) without crystallization, has high solubility in cyclohexanone, methyl ethyl ketone or like organic solvents, exhibits excellent coating properties and orientation properties, and, after polymerization, has high transparency. wherein R1 and R2 each represent hydrogen, a methyl group or halogen; rings A to C each represent a benzene ring, a naphthalene ring, etc.; at least one of rings A to C is a fused ring; X, Y, and Z each represent a C1 to C6 alkyl group, etc.; L1, L2, and L3 each represent —COO—, —OCO—, —O(CH2)j— (j=1 to 8), etc.; n is 0 or 1, and a to c are numbers such that the polymerizable liquid crystal compound may have at least one of X, Y, and Z.

Abstract: A novel polymerizable compound of the present invention is represented by the following general formula (I). Due to the presence of a reactive phenolic hydroxyl group at the end of the molecule, it can be reacted easily with various functional compounds and is useful as a monomer and an intermediate for various functional materials, especially as an intermediate for a polymerizable liquid crystal material. wherein R1 is a hydrogen atom, a methyl group or a halogen atom; R2 is an optionally substituted alkyl group having 1 to 6 carbon atoms, an optionally substituted alkoxy group having 1 to 6 carbon atoms, a halogen atom or a cyano group; an alkylene group of each of the alkyl and the alkoxy group may be interrupted by an unsaturated bond, an ether bond, a thioether bond or an ester bond; n is an integer from 0 to 14; and m is 0 or 1.

Abstract: A polymer compound which is useful as a light emitting material and a charge transporting material and excellent in electron injection property, comprising as a partial structure therein a structure of the following formula (a) is provided: (wherein, a ring A and a ring B represent each independently an aromatic ring or a non-aromatic ring, and at least one of the ring A and the ring B is an aromatic ring. A ring C represents an aromatic ring. Z1 represents an atom selected from a carbon atom, oxygen atom, sulfur atom, nitrogen atom, silicon atom, boron atom, phosphorus atom and selenium atom or a group containing the atom, and Z2 to Z6 represent each independently an atom selected from a carbon atom, silicon atom, nitrogen atom and boron atom or a group containing the atom.).

Abstract: The invention includes compounds represented by Formula (1): wherein R represents hydrogen or methyl; A represents alkylene having from 1 to 12 carbon atoms, wherein in the alkylene, arbitrary —CH2— may be replaced by —O—, —S—, —CH?CH—, —CO—, —COO— or —OCO—; X and Y each independently represent an aromatic ring or a cyclohexane ring, wherein in the rings, arbitrary hydrogen may be replaced by alkyl having from 1 to 3 carbon atoms; Z independently represents a single bond, —O—, —S—, —COO—, —OCO—, —CON(R1)— or —N(R1)CO—, wherein R1 represents hydrogen or methyl; and m represents an integer of from 0 to 3.

Abstract: The polymerizable compound of the present invention is represented by general formula (1) below and can provide a composition that is polymerizable near ambient temperature and exists in a liquid crystal phase at low temperatures. The composition and a (co)polymer of the polymerizable compound of the present invention are liquid crystal substances useful as optically anisotropic materials. (In the formula, each of rings A1 to A3 represents a benzene ring, cyclohexane ring, etc.; each of X to Z represents a C1-8 alkyl or alkoxy group, C2-6 alkenyl group, halogen atom, cyano group, or CH2?CR3—COO—; each of R1 to R3 represents a hydrogen atom, methyl group, or halogen atom; each of L1 to L3 represents —CH2CH2COO—, —COO—, —OCO—, —CH2CH2—, —O(CH2)f— (herein, f=1-8), etc.; n represents 0 or 1; and a to c represent such numbers that the polymerizable compound has at least one or more of any of X, Y, and Z).

Abstract: The present invention relates to new phenylic derivatives exhibiting a good affinity for certain sub-types of cannabinoid receptors, in particular the CB2 receptors. These derivatives are of particular interest in a method for treating pathological conditions and diseases in which one or more cannabinoid receptors are involved. The invention also relates to pharmaceutical compositions containing said new phenylic derivatives and to methods for the preparation and use thereof.